SEARCH:   Advanced

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Cartron, G. Articles by Watier, H. Search for Related Content PubMed PubMed Citation Articles by Cartron, G. Articles by Watier, H. Related Collections Neoplasia Plenary Papers Related Letter in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 February 2002, Vol. 99, No. 3, pp. 754-758 PLENARY PAPER Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcRIIIa gene Guillaume Cartron, Laurent Dacheux, Gilles Salles, Philippe Solal-Celigny, Pierre Bardos, Philippe Colombat, and Hervé Watier From Service d'Oncologie Médicale et Maladies du Sang et Laboratoire d'Immunologie, Centre Hospitalier Régional et Universitaire de Tours and UPRES-EA 3249 "Cellules hématopoïétiques, hémostase et greffe," Université de Tours; and Service d'Hématologie, Centre Hospitalier Lyon-Sud et Centre Jean Bernard, Le Mans, France.     Abstract Top Abstract Introduction Patients, materials, and... Results Discussion References Given that the FcRIIIa receptor 158V allotype displays a higher affinity for human immunoglobulin G1 and increased antibody-dependent cellular cytotoxicity, the aim of this study was to determine the influence of that FCGR3A polymorphism on the therapeutic response to rituximab, an anti-CD20 humanized immunoglobulin G1 increasingly used in the treatment of non-Hodgkin lymphomas. The FCGR3A-158V/F genotype was determined in 49 patients having received rituximab for a previously untreated follicular non-Hodgkin lymphoma. The clinical response and the disappearance of the BCL2-JH gene rearrangement in both peripheral blood and bone marrow were evaluated at 2 months (M2) and at 1 year (M12). The study population consisted of 20% FCGR3A-158V homozygous patients, 35% FCGR3A-158F homozygous patients, and 45% heterozygous patients (FCGR3A-158F carriers). The objective response rates at M2 and M12 were 100% and 90%, respectively, in FCGR3A-158V homozygous patients compared with 67% (P = .03) and 51% (P = .03), respectively, in FCGR3A-158F carriers. A disappearance of the BCL2-JH gene rearrangement in both peripheral blood and marrow was observed at M12 in 5 of 6 of homozygous FCGR3A-158V patients compared with 5 of 17 of FCGR3A-158F carriers (P = .03). The homozygous FCGR3A-158V genotype was confirmed to be the single parameter associated with clinical and molecular responses by multivariate analysis. This study showed an association between the FCGR3A genotype and clinical and molecular responses to rituximab. This finding will certainly give rise to new pharmacogenetic approaches to the management of patients with non-Hodgkin lymphomas. (Blood. 2002;99:754-758) © 2002 by The American Society of Hematology.     Introduction Top Abstract Introduction Patients, materials, and... Results Discussion References Rituximab (Mabthera, Rituxan) is a chimeric anti-CD20 immunoglobulin G1 (IgG1) monoclonal antibody consisting of human 1 and  constant regions linked to murine variable domains.1 Over the last few years, rituximab has considerably modified the therapeutic strategy for B lymphoproliferative malignancies, particularly non-Hodgkin lymphomas (NHLs). Rituximab, alone or in combination with chemotherapy, was shown to be effective in the treatment of both low-intermediate2-8 and high-grade NHL.6,9 Unfortunately, 30% to 50% of patients with low-grade NHL exhibit no clinical response to rituximab.4,5 It has been suggested that the level of CD20 expression on lymphoma cells,2 the presence of high tumor burden at the time of treatment,6 or low serum rituximab concentrations2,10 may explain the lack of efficacy of rituximab in some patients. Nevertheless, the actual causes of treatment failure remain largely unknown. In vitro studies suggest that rituximab induces lymphoma cell lysis in vitro through antibody-dependent cell-mediated cytotoxicity (ADCC),11,12 complement-dependent cytotoxicity,11,13,14 or direct signaling leading to apoptosis.15,16 ADCC is an important effector mechanism in the eradication of intracellular pathogens and tumor cells. It requires leukocyte receptors for the Fc portion of IgG (FcR), whose function is to link the IgG-sensitized antigens to FcR-bearing cytotoxic cells and to trigger the cell activation mechanisms. The role of ADCC is still controversial,13,14 but the implication of FcR in the antitumor effects of anti-CD20 antibodies against human lymphoma cell lines has been demonstrated in murine models.17-19 Three classes of FcR (FcRI, FcRII, and FcRIII) and their subclasses are encoded by 8 genes in humans, all located on the long arm of chromosome 1. Some of those genes display a functional allelic polymorphism generating allotypes with different receptor properties. Those polymorphisms have been identified as genetic factors that increase susceptibility to autoimmune or infectious diseases.20-22 One of those genetic factors is a gene dimorphism in FCGR3A, which encodes FcRIIIa with either a phenylalanine (F) or a valine (V) at amino acid position 158.23,24 This residue directly interacts with the lower hinge region of IgG1, as recently shown by IgG1-FcRIII cocrystallization.25 It has been clearly demonstrated that human IgG1 binds more strongly to homozygous FcRIIIa-158V natural killer (NK) cells than to homozygous FcRIIIa-158F or heterozygous NK cells.23,24 Because FcRIIIa is expressed on both NK cells and macrophages, which are the most important natural cytotoxic effectors, we have formulated the hypothesis that FCGR3A gene dimorphism may influence the response to rituximab. Genotyping of FCGR3A was therefore performed on patients with previously untreated follicular NHL who had received rituximab alone, a particular situation in which the response rate is very high.5 FCGR2A-131H/R was also determined as a control because that gene colocalizes with FCGR3A on chromosome 1q22 and encodes the macrophage FcRIIa receptor.     Patients, materials, and methods Top Abstract Introduction Patients, materials, and... Results Discussion References Patients and treatment Clinical trial design, eligibility criteria, and end-point assessment have been previously reported.5 In brief, patients were eligible for inclusion in this study if they had previously untreated follicular CD20+ NHL according to the REAL classification.26 Patients were required to present with stage II to IV disease according to the Ann-Arbor classification and at least one measurable disease site. All patients were required to have low tumor burden according to the GELF criteria.27 A total of four 375 mg/m2 doses of rituximab (Roche, Neuilly, France) were administered by intravenous infusion (days 1, 8, 15, 22). The management of infusion and adverse events has already been reported.5 The study protocol was approved by an ethics committee, and all patients gave their informed consent. Monitoring and end points Baseline evaluation included clinical examination, chest x-ray, unilateral bone marrow biopsy, and computed tomography of the chest, abdomen, and pelvis. Response was assessed by an independent panel of radiologists who reviewed all the computed tomography scans of the included patients. The primary efficacy end point was the objective response rate, ie, the proportion of patients achieving either complete remission (CR), unconfirmed CR (CRu), or partial response (PR) according to the criteria recently proposed by an international expert committee.28 Clinical response was evaluated at days 50 and 78. Only the maximum response was taken into account, and that assessment time point was named M2. All patients were evaluated for progression at 1 year (M12). Patients in CR or CRu with disappearance of bone marrow infiltration at M2 and reappearance of lymphoma cells in bone marrow at M12 were considered "progressive"; patients in PR with negative bone marrow biopsy at M2 and positive biopsy at M12 were considered in PR. Molecular analysis of the BCL2-JH gene rearrangement was performed by polymerase chain reaction (PCR), as previously described,5 on a lymph node obtained at diagnosis and on both peripheral blood and bone marrow at diagnosis, M2, and M12. FCGR3A-158V/F genotyping Of the 50 patients included in the clinical trial, one patient was excluded after histologic review. Forty-nine patients were therefore available for FCGR3A genotype analysis. All samples were analyzed in the same laboratory, and the DNA was extracted using standard procedures. DNA was isolated from peripheral blood (n = 46) or bone marrow (n = 3). Genotyping of FCGR3A-158V/F polymorphism was performed as described by Koene et al23 using a nested PCR followed by allele-specific restriction enzyme digestion. Briefly, 2 FCGR3A-specific primers (5'-ATATTTACAGAATGGCACAGG-3', 5'-GACTTGGTACCCAGGTTGAA-3') (Eurobio, Les Ulis, France) were used to amplify a 1.2 kilobase fragment containing the polymorphic site. The initial PCR assay was performed with 1.25 µg genomic DNA, 200 ng of each primer, 200 µM of each deoxyribonucleoside triphosphate (dNTP) (MBI Fermentas, Vilnius, Lithuania), and 1 U Taq DNA polymerase (Promega, Charbonnière, France) as recommended by the manufacturer. This first PCR consisted of 10 minutes at 95°C, then 35 cycles (each consisting of steps at 95°C for 1 minute, 57°C for 1.5 minutes, and 72°C for 1.5 minutes), and 8 minutes at 72°C to achieve complete extension. The second PCR used primers (5'-ATCAGATTCGATCCTACTTCTGCAGGGGGCAT-3', 5'-ACGTGCTGAGCTTGAGTGATGGTGATGTTCAC-3') (Eurobio) amplifying a 94 base pair (bp) fragment and creating an NlaIII restriction site only in the FCGR3A-158V allele. This nested PCR was performed with 1 µL of the amplified DNA, 150 ng of each primer, 200 µM of each dNTP, and 1 U of Taq DNA polymerase. The first cycle consisted of 5 minutes at 95°C, then 35 cycles (each consisting of steps at 95°C for 1 minute, 64°C for 1 minute, and 72°C for 1 minute), and 9.5 minutes at 72°C to complete extension. The amplified DNA (10 µL) was then digested with 10 U NlaIII (New England Biolabs, Hitchin, England) at 37°C for 12 hours and separated by electrophoresis on 8% polyacrylamide gel. After staining with ethidium bromide, DNA bands were visualized under UV light. For homozygous FCGR3A-158F patients, only one undigested band (94 bp) was visible. Three bands (94 bp, 61 bp, and 33 bp) were seen in heterozygous individuals, whereas for homozygous FCGR3A-158V patients only 2 digested bands (61 bp and 33 bp) were obtained. FCGR2A-131H/R genotyping Genotyping of FCGR2A-131H/R consisted of PCR followed by an allele-specific restriction enzyme digestion, according to Liang et al.29 The sense primer (5'-GGAAAATCCCAGAAATTCTCGC-3') (Eurobio) was modified to create a BstUI restriction site, in case of an R allele, while the antisense primer (5'-CAACAGCCTGACTACCTATTACGCGGG-3') (Eurobio) was modified to carry a second BstUI restriction site that served as an internal control. PCR amplification was performed in a 50 µL reaction with 1.25 µg genomic DNA, 170 ng of each primer, 200 µM of each dNTP, 0.5 U Taq DNA polymerase, and the manufacturer's buffer. The first cycle consisted of 3 minutes at 94°C followed by 35 cycles (each consisting of 3 steps at 94°C for 15 seconds, 55°C for 30 seconds, and 72°C for 40 seconds) and 7 minutes at 72°C to complete extension. The amplified DNA (7 µL) was then digested with 20 U BstUI (New England Biolabs) at 60°C for 12 hours. Further analysis was performed as described for FCGR3A genotyping. The FCGR2A-131H and -131R alleles were visualized as 337 bp and 316 bp DNA fragments, respectively. Statistical analysis The clinical and laboratory characteristics and the clinical and molecular responses of the patients in the different genotypic groups were compared using the Fisher exact test. A logistic regression analysis including sex, age (> or  60 years), number of extranodal sites involved ( or < 2), bone marrow involvement, BCL2-JH rearrangement status at diagnosis, and FCGR3A genotype was used to identify independent prognostic variables influencing the clinical and molecular responses. Progression-free survival was calculated using the method of Kaplan and Meier30 and was measured from the start of treatment until progression, relapse, or death. Comparison of the progression-free survival by FCGR3A genotype was performed using the log-rank test. The significance level was P < .05.     Results Top Abstract Introduction Patients, materials, and... Results Discussion References Clinical response Of the 49 patients tested for the FCGR3A-158V/F polymorphism, 10 (20%) and 17 (35%) were homozygous for FCGR3A-158V and FCGR3A-158F, respectively, and 22 (45%) were heterozygous. The 3 groups were not different in terms of sex, disease stage, bone marrow involvement, number of extranodal sites involved, or presence of BCL2-JH rearrangement in peripheral blood and bone marrow at diagnosis (Table 1). No difference was found when homozygous FCGR3A-158V patients were compared with FCGR3A-158F carriers (FCGR3A-158F homozygous and heterozygous patients) or when homozygous FCGR3A-158F patients were compared with FCGR3A-158V carriers (FCGR3A-158V homozygous and heterozygous patients). The objective response rate at M2 was 100% (CR + CRu = 40%), 70% (CR + CRu = 29%), and 64% (CR + CRu = 18%) in FCGR3A-158V homozygous, FCGR3A-158F homozygous, and heterozygous patients, respectively (P = .09). A significant difference in objective response rate was observed between FCGR3A-158V homozygous patients and FCGR3A-158F carriers, with a 67% (CR + CRu = 23%) objective response rate for this latter group (relative risk = 1.5; 95% [confidence interval] CI, 1.2-1.9; P = .03) (Table 2). No difference was observed between FCGR3A-158F homozygous patients and FCGR3A-158V carriers. At M12, the objective response rate was 90% (CR + CRu = 70%), 59% (CR + CRu = 35%), and 45% (CR + CRu = 32%) in FCGR3A-158V homozygous, FCGR3A-158F homozygous, and heterozygous patients, respectively (P = .06). The difference in objective response rate was still present 1 year after treatment between the FCGR3A-158V homozygous group and FCGR3A-158F carriers, with a 51% (CR + CRu = 33%) objective response rate for this latter group (relative risk = 1.7; 95% CI, 1.2-2.5; P = .03). The logistic regression analysis showed that the homozygous FCGR3A-158V genotype was the only predictive factor for clinical response both at M2 (P = .02) and at M12 (P = .01). The progression-free survival at 3 years (median follow-up 35 months; range 31-41) (Figure 1) was 56% in FCGR3A-158V homozygous patients and 35% in FCGR3A-158F carriers (nonsignificant). Of the 45 patients analyzed for FCGR2A-131H/R polymorphism, 9 (20%) and 13 (29%) were homozygous for FCGR2A-131R and FCGR2A-131H, respectively, while 23 (51%) were heterozygous. There was no difference in the characteristics at inclusion or clinical response to rituximab treatment for these 3 groups or for homozygous FCGR2A-131H patients and FCGR2A-131R carriers or for homozygous FCGR2A-131R patients and FCGR2A-131H carriers (data not shown).                                View this table: [in this window] [in a new window]   Table 1. Characteristics of patients by FCGR3A-158V/F polymorphism                                View this table: [in this window] [in a new window]   Table 2. Clinical response to rituximab by FCGR3A-158V/F polymorphism View larger version (14K): [in this window] [in a new window]   Figure 1. Adjusted Kaplan-Meier estimates of progression-free survival after rituximab treatment by FCGR3A-158V/F genotype (P = .2). Molecular response At diagnosis, BCL2-JH rearrangement was detected in both peripheral blood and in bone marrow in 30 (64%) patients, enabling further follow-up. Twenty-five patients (6 FCGR3A-158V homozygous patients and 19 FCGR3A-158F carriers) and 23 patients (6 FCGR3A-158V homozygous patients and 17 FCGR3A-158F carriers) were analyzed for BCL2-JH rearrangement in both peripheral blood and bone marrow at M2 and at M12 (Table 3). At M2, a cleaning of BCL2-JH rearrangement was observed in 3 of 6 of the FCGR3A-158V homozygous patients and in 5 of 19 of the FCGR3A-158F carriers (nonsignificant). In contrast, the rate of BCL2-JH rearrangement cleaning at M12 was higher (5 of 6) in the FCGR3A-158V homozygous patients than in the FCGR3A-158F carriers (5 of 17) (relative risk = 2.8; 95% CI, 1.2-6.4; P = .03). The logistic regression analysis showed that the FCGR3A-158V homozygous genotype was the only factor associated with a greater probability of exhibiting BCL2-JH rearrangement cleaning at M12 (P = .04). The single homozygous FCGR3A-158V patient still presenting with BCL2-JH rearrangement in peripheral blood and bone marrow at M12 was in CR 23 months after rituximab treatment. In contrast, the molecular responses at M2 and M12 were not influenced by the FCGR2A-131H/R polymorphism (data not shown).                                View this table: [in this window] [in a new window]   Table 3. Molecular response to rituximab at M2 and at M12 by FCGR3A-158V/F polymophism     Discussion Top Abstract Introduction Patients, materials, and... Results Discussion References Because of the increasing use of rituximab in B-cell lymphoproliferative malignancies, enhanced understanding of treatment failures and of the mode of action of rituximab is required. Given the expected role of NK cell and macrophage FcRIIIa in rituximab-dependent cellular cytotoxicity against lymphoma cells, we genotyped FCGR3A in follicular NHL patients with well-defined clinical and laboratory characteristics and treated with rituximab alone.5 In particular, all the patients included in this study had a low tumor burden NHL and a molecular analysis of BCL2-JH at diagnosis and during follow-up. The FCGR3A allele frequencies in this population were similar to those of a general Caucasian population.23,24 Our results show an association between the FCGR3A genotype and the response to rituximab. Indeed, homozygous FCGR3A-158V patients, who account for one fifth of the population, had a greater probability of experiencing clinical response, with 100% and 90% objective response rates at M2 and M12, respectively. Moreover, 5 of the 6 FCGR3A-158V homozygous patients analyzed for BCL2-JH rearrangement showed molecular response at M12, compared with 5 of the 17 FCGR3A-158F carriers. FCGR3A-158V homozygosity was the only factor associated with the clinical and molecular responses. However, these higher clinical and molecular responses were still insufficient to significantly improve the progression-free survival in homozygous FCGR3A-158V patients. This is the first report of an easily assessable genetic predictive factor for both clinical and molecular responses to rituximab. However, the genetic association does not demonstrate that the mode of action of rituximab involves FcRIIIa. The association observed between FCGR3A genotype and response to rituximab might be due to another genetic polymorphism in linkage disequilibrium. Those polymorphisms could be located in FCGR3A itself, such as the triallelic FCGR3A-48L/H/R polymorphism,31 or in other FcR-coding genes, because FCGR3A is located on the long arm of chromosome 1, which includes the 3 FCGR2 genes and FCGR3B.32 A linkage disequilibrium has been reported between FCGR2A and FCGR3B.33 However, the fact that FCGR2A-131H/R polymorphism was not associated with a better response to rituximab strongly supports the fact that a gene very close to FCGR3A or FCGR3A itself is directly involved. Several in vitro studies argue in favor of direct involvement of FCGR3A-158V/F polymorphism. First, Koene et al23 have shown that the previously reported differences in IgG binding among the 3 FcRIIIa-48L/H/R isoforms31 are a consequence of the linked FcRIIIa-158V/F polymorphism, and several teams have demonstrated that NK cells from individuals homozygous for the FCGR3A-158V allotype have a higher affinity for human complexed IgG1 and are more cytotoxic toward IgG1-sensitized targets.23,24,34 In conjunction with our present results, those functional differences strongly suggest that FCGR3A-158V homozygous patients have a better response to rituximab because of a better in vivo binding of that chimeric human IgG1 to FcRIIIa. Secondly, NK cell- and macrophage-mediated ADCC is one of the mechanisms triggered by anti-CD20 antibodies in vitro8,11,12 as well as in murine models in vivo,17-19 and rituximab-mediated apoptosis is amplified by FcR-expressing cells.15,16 Of all FcR, FcRIIIa is the only receptor shared by NK cells and macrophages. We thus postulate that FCGR3A-158V patients show a better response to rituximab because they have better ADCC activity against lymphoma cells. The fact that more than 50% of the FCGR3A-158F carriers nonetheless present a clinical response to rituximab could be explained by lower, but still sufficient, ADCC activity or, more likely, by other mechanisms operating in vivo such as complement-dependent cytotoxicity, complement-dependent cell-mediated cytotoxicity,11,13,14 and/or apoptosis.15,16 ADCC could then be viewed as an additional mechanism in the response to rituximab that is particularly effective in FCGR3A-158V homozygous patients. The in vitro studies suggest a "gene-dose" effect with a level of IgG1 binding to NK cells from FCGR3A heterozygous donors intermediate between that observed with NK cells from FCGR3A-158V and FCGR3A-158F homozygotes.23 However, the clinical response of heterozygous patients appears similar to that of FCGR3A-158F homozygous patients. Further studies with larger groups of patients will be required to conclude against a "gene-dose" effect in vivo. Because FcRIIIa is strongly associated with a better response to rituximab, it needs to be taken into account in the development of new drugs targeting the CD20 antigen. For example, it may be possible to use engineered rituximab to treat FCGR3A-158F-carrier patients with B-cell lymphomas. Indeed, by modifying various residues in the IgG1 lower hinge region, Shields et al have recently obtained IgG1 mutants that bind more strongly to FcRIIIa-158F than native IgG1.34 Taken together, those results will enable new therapeutic strategies against B lymphoproliferative disorders based upon prior determination of the patient's FCGR3A genotype. Because this polymorphism has the same distribution in various ethnic populations, including blacks and Japanese, such a strategy may be applied worldwide.23,35,36 Furthermore, such a pharmacogenetic approach may also be applied to other intact humanized IgG1 antibodies used in the treatment of B-cell malignancies, such as Campath-1H, or those used in the treatment of other malignancies, such as trastuzumab (Herceptin). Even more generally, this approach may apply to other intact humanized IgG1 developed to deplete target cells.     Acknowledgments The authors thank Dr S. Iochman for her technical help in molecular biology assays and Prof G. Thibault and Prof G Paintaud for their critical review of the manuscript.     Footnotes Submitted June 8, 2001; accepted October 2, 2001. Supported by grants from the Fondation Langlois and the Comité de l'Indre de la Ligue Nationale Contre le Cancer. The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734. Reprints: Hervé Watier, Laboratoire d'Immunologie, Centre Hospitalier Universitaire, 2 boulevard Tonnellé, 37044 Tours Cedex, France; e-mail: watier{at}med.univ-tours.fr.     References Top Abstract Introduction Patients, materials, and... Results Discussion References 1. Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood. 1994;84:2457-2466[Abstract/Free Full Text]. 2. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825-2833[Abstract]. 3. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997;90:2188-2195[Abstract/Free Full Text]. 4. Hainsworth JD, Burris HA III, Morrissey LH, et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood. 2000;95:3052-3056[Abstract/Free Full Text]. 5. Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as first-line therapy of follicular lymphoma patients with low tumor burden: clinical and molecular evaluation. Blood. 2001;97:101-106[Abstract/Free Full Text]. 6. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998;92:1927-1932[Abstract/Free Full Text]. 7. Foran JM, Rohatiner AZ, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol. 2000;18:317-324[Abstract/Free Full Text]. 8. Anderson DR, Grillo-Lopez A, Varns C, Chambers KS, Hanna N. Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem Soc Trans. 1997;25:705-708[Medline] [Order article via Infotrieve]. 9. Vose J, Link B, Grossbard M, et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated intermediate or high-grade non-Hodgkin's lymphoma (NHL). Ann Oncol. 1999;10:58a. 10. Berinstein NL, Grillo-Lopez AJ, White CA, et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non- Hodgkin's lymphoma. Ann Oncol. 1998;9:995-1001[Abstract/Free Full Text]. 11. Harjunpaa A, Junnikkala S, Meri S. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol. 2000;51:634-641[CrossRef][Medline] [Order article via Infotrieve]. 12. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435-445[Abstract/Free Full Text]. 13. Idusogie EE, Presta LG, Gazzano-Santoro H, et al. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol. 2000;164:4178-4184[Abstract/Free Full Text]. 14. Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood. 2000;95:3900-3908[Abstract/Free Full Text]. 15. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood. 1998;91:1644-1652[Abstract/Free Full Text]. 16. Shan D, Ledbetter JA, Press OW. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother. 2000;48:673-683[CrossRef][Medline] [Order article via Infotrieve]. 17. Hooijberg E, Sein JJ, van den Berk PC, et al. Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2. Cancer Res. 1995;55:2627-2634[Abstract/Free Full Text]. 18. Funakoshi S, Longo DL, Murphy WJ. Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas. J Immunother Emphasis Tumor Immunol. 1996;19:93-101[Medline] [Order article via Infotrieve]. 19. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med. 2000;6:443-446[CrossRef][Medline] [Order article via Infotrieve]. 20. Fijen CA, Bredius RG, Kuijper EJ, et al. The role of Fc receptor polymorphisms and C3 in the immune defence against Neisseria meningitidis in complement-deficient individuals. Clin Exp Immunol. 2000;120:338-345[CrossRef][Medline] [Order article via Infotrieve]. 21. Dijstelbloem HM, Scheepers RH, Oost WW, et al. Fc receptor polymorphisms in Wegener's granulomatosis: risk factors for disease relapse. Arthritis Rheum. 1999;42:1823-1827[CrossRef][Medline] [Order article via Infotrieve]. 22. Myhr KM, Raknes G, Nyland H, Vedeler C. Immunoglobulin G Fc-receptor (FcR) IIA and IIIB polymorphisms related to disability in MS. Neurology. 1999;52:1771-1776[Abstract/Free Full Text]. 23. Koene HR, Kleijer M, Algra J, et al. Fc RIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc RIIIa, independently of the Fc RIIIa-48L/R/H phenotype. Blood. 1997;90:1109-1114[Abstract/Free Full Text]. 24. Wu J, Edberg JC, Redecha PB, et al. A novel polymorphism of FcRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest. 1997;100:1059-1070[Medline] [Order article via Infotrieve]. 25. Sondermann P, Huber R, Oosthuizen V, Jacob U. The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc RIII complex. Nature. 2000;406:267-273[CrossRef][Medline] [Order article via Infotrieve]. 26. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361-1392[Free Full Text]. 27. Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 1997;15:1110-1117[Abstract/Free Full Text]. 28. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244[Abstract/Free Full Text]. 29. Jiang XM, Arepally G, Poncz M, McKenzie SE. Rapid detection of the Fc  RIIA-H/R 131 ligand-binding polymorphism using an allele-specific restriction enzyme digestion (ASRED). J Immunol Methods. 1996;199:55-59[CrossRef][Medline] [Order article via Infotrieve]. 30. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481[CrossRef]. 31. de Haas M, Koene HR, Kleijer M, et al. A triallelic Fc  receptor type IIIA polymorphism influences the binding of human IgG by NK cell Fc  RIIIa. J Immunol. 1996;156:3948-3955. 32. Peltz GA, Grundy HO, Lebo RV, Yssel H, Barsh GS, Moore KW. Human Fc  RIII: cloning, expression, and identification of the chromosomal locus of two Fc receptors for IgG. Proc Natl Acad Sci U S A. 1989;86:1013-1017[Abstract/Free Full Text]. 33. Schnackenberg L, Flesch BK, Neppert J. Linkage disequilibria between Duffy blood groups, Fc  IIa and Fc  IIIb allotypes. Exp Clin Immunogenet. 1997;14:235-242[Medline] [Order article via Infotrieve]. 34. Shields RL, Namenuk AK, Hong K, et al. High resolution mapping of the binding site on human IgG1 for Fc  RI, Fc  RII, Fc  RIII, and FcRn and design of IgG1 variants with improved binding to the Fc  R. J Biol Chem. 2001;276:6591-6604[Abstract/Free Full Text]. 35. Leppers-van de Straat FG, van der Pol W, Jansen MD, et al. A novel PCR-based method for direct Fc receptor IIIa (CD16) allotyping. J Immunol Methods. 2000;242:127-132[CrossRef][Medline] [Order article via Infotrieve]. 36. Lehrnbecher T, Foster CB, Zhu S, et al. Variant genotypes of the low-affinity Fc receptors in two control populations and a review of low-affinity Fc receptor polymorphisms in control and disease populations. Blood. 1999;94:4220-4232[Abstract/Free Full Text]. © 2002 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Letter in Blood Online: Implication for how the single nucleotide polymorphism (SNP) of Fc receptor, FcRIIIa alters the interaction with anti-CD20 monoclonal antibody Yasuo Oshima, Akio Fujimura, Guillaume Cartron, Laurent Dacheux, Gilles Salles, Philippe Solal-Celigny, Pierre Bardos, Philippe Colombat, and Hervé Watier Blood 2002 99: 4649-4650. [Full Text] [PDF] This article has been cited by other articles: V. Minard-Colin, Y. Xiu, J. C. Poe, M. Horikawa, C. M. Magro, Y. Hamaguchi, K. M. Haas, and T. F. Tedder Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage Fc{gamma}RI, Fc{gamma}RIII, and Fc{gamma}RIV Blood, August 15, 2008; 112(4): 1205 - 1213. [Abstract] [Full Text] [PDF] C. Meyer zum Buschenfelde, Y. Feuerstacke, K. S. Gotze, K. Scholze, and C. Peschel GM1 Expression of Non-Hodgkin's Lymphoma Determines Susceptibility to Rituximab Treatment Cancer Res., July 1, 2008; 68(13): 5414 - 5422. [Abstract] [Full Text] [PDF] P. V. Beum, M. A. Lindorfer, F. Beurskens, P. T. Stukenberg, H. M. Lokhorst, A. W. Pawluczkowycz, P. W. H. I. Parren, J. G. J. van de Winkel, and R. P. Taylor Complement Activation on B Lymphocytes Opsonized with Rituximab or Ofatumumab Produces Substantial Changes in Membrane Structure Preceding Cell Lysis J. Immunol., July 1, 2008; 181(1): 822 - 832. [Abstract] [Full Text] [PDF] C. A. Walshe, S. A. Beers, R. R. French, C. H. T. Chan, P. W. Johnson, G. K. Packham, M. J. Glennie, and M. S. Cragg Induction of Cytosolic Calcium Flux by CD20 Is Dependent upon B Cell Antigen Receptor Signaling J. Biol. Chem., June 20, 2008; 283(25): 16971 - 16984. [Abstract] [Full Text] [PDF] G. Cartron, L. Zhao-Yang, M. Baudard, T. Kanouni, V. Rouille, P. Quittet, B. Klein, and J.-F. Rossi Granulocyte-Macrophage Colony-Stimulating Factor Potentiates Rituximab in Patients With Relapsed Follicular Lymphoma: Results of a Phase II Study J. Clin. Oncol., June 1, 2008; 26(16): 2725 - 2731. [Abstract] [Full Text] [PDF] H Marotte, G Paintaud, H Watier, and P Miossec Rituximab-related late-onset neutropenia in a patient with severe rheumatoid arthritis Ann Rheum Dis, June 1, 2008; 67(6): 893 - 894. [Full Text] [PDF]